stock-detail (AEZS)

Oncology Corporate Profile

Company Description

This company does not have any commercial products

This company does not have any pipeline products

Recent News Headlines

4/23/2017 12:17 pm

4/23/2017 12:17 pm

4/23/2017 12:17 pm

4/23/2017 12:17 pm

4/23/2017 12:17 pm

Aeterna Zentaris Mails Management Information Circular in Connection with Annual Meeting of Shareholders

4/3/2017 12:00 pm

[Business Wire] - Aeterna Zentaris Inc. today announced that it has mailed a Notice of Meeting and Management Information Circular to the shareholders of record as of March 20, 2017 in connection with its Annual Meeting of shareholders to be held at the offices of Norton Rose Fulbright Canada, 1 Place Ville-Marie, Suite 2500, in Montreal, Canada on Tuesday, May 9, 2017 at 10:00 a.m.

Aeterna Zentaris Intends to File NDA with Respect to Macrilen™ in Third Quarter of 2017

3/30/2017 12:00 pm

[Business Wire] - Aeterna Zentaris Inc. today announced that, following its meeting with the U.S. Food and Drug Administration on March 29, 2017, the Company intends to file a new drug application seeking approval of Macrilen™ for the evaluation of growth hormone deficiency in adults .

Aeterna Zentaris Announces At the Market Issuance Program

3/28/2017 09:00 pm

[Business Wire] - Aeterna Zentaris Inc. :

Aeterna Zentaris Reports Fourth Quarter and Full-Year 2016 Financial and Operating Results

3/15/2017 08:04 pm

[Business Wire] - Aeterna Zentaris Inc. , a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology and endocrinology, today reported financial and operating results for the fourth quarter and year ended December 31, 2016.

Aeterna Zentaris Announces EMA Pediatric Committee Agreement on the Pediatric Investigation Plan for Macrilen™

3/7/2017 01:03 pm

[Business Wire] - Aeterna Zentaris Inc. announced today that the Pediatric Committee of the European Medicines Agency agreed to the Company’s Pediatric Investigation Plan for Macrilen™ and agreed that the Company may defer conducting the PIP until after it files a Marketing Authorization Application seeking marketing authorization for the use of Macrilen™ for the evaluation of adult growth hormone deficiency.

Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2016 Financial and Operating Results on March 15, 2017

3/6/2017 01:03 pm

[Business Wire] - Aeterna Zentaris Inc. will announce its fourth quarter and full-year 2016 financial and operating results after market close on Wednesday, March 15, 2017.

Aeterna Zentaris Announces Presentation Regarding Macrilen™ at 99th Annual Meeting of the Endocrine Society

3/2/2017 10:00 pm

[Business Wire] - Aeterna Zentaris Inc. today announced that Jose M. Garcia, M.D., Ph.D., an Associate Professor of Medicine at the Puget Sound Veterans Administration Hospital and the University of Washington, will present an abstract entitled “Validation of Macimorelin as a Diagnostic Test for Adult Growth Hormone Deficiency : A Phase 3 Study in Comparison with the Insulin Tolerance Test ” from 1:00 pm through 3:00 ...

Aeterna Zentaris Announces Zoptrex™ Presentation in Prostate Cancer at 2017 Genitourinary Cancers Symposium

2/14/2017 10:03 pm

[Business Wire] - Aeterna Zentaris Inc. today announced that a poster entitled, “A phase II trial of zoptarelin doxorubicin in castration-and taxane-resistant prostate cancer”, will be presented during the 2017 Genitourinary Cancers Symposium’s “Translating Research to Value-based and Patient-centric Care” by lead investigator, and co-author of the presentation, Jacek Pinski, MD, PhD, USC Norris Comprehensive Cancer ...

Aeterna Zentaris Announces Plans to Pursue FDA Registration of Macrilen™

2/13/2017 12:03 pm

[Business Wire] - Aeterna Zentaris Inc. today announced that, following a comprehensive review of data obtained from the confirmatory Phase 3 clinical trial of Macrilen™ for the evaluation of growth hormone deficiency in adults , using the insulin tolerance test as a comparator, it concluded that Macrilen™ demonstrated performance supportive of achieving registration with the U.S.

Aeterna Zentaris to Present at the 2nd Annual Disruptive Growth & Healthcare Conference

2/9/2017 01:03 pm

[Business Wire] - Aeterna Zentaris Inc. , announced today that it will be presenting at the 2nd Annual Disruptive Growth & Healthcare Conference on Thursday, February 16 at 9:30 AM EST.

Aeterna Zentaris to Present at the 2017 BIO CEO and Investor Conference

2/7/2017 09:01 pm

[Business Wire] - Aeterna Zentaris Inc. today announced that it will be presenting at the 2017 BIO CEO & Investor Conference on Monday, February 13 at 8:00 AM EST in New York City.

Drug Approvals Expected to Rise as Trump Pledges to Speed Up Approval Process: Latest Reports on AEterna Zentaris and Momenta Pharmaceuticals

2/1/2017 02:04 pm

[Accesswire] - NEW YORK, NY / ACCESSWIRE / February 1, 2017 / The Biotech Industry has outperformed the broader markets in 2017, despite all the criticism drug makers have been facing. The iShares NASDAQ Biotechnology ...